Table 3.
150 mg RBT EOD with LPV/r (400 mg/100 mg) (n = 9) |
300 mg RBT EOD with LPV/r (400 mg/100 mg) (n = 7) |
pvalue | |
---|---|---|---|
(Median + IQR) | (Median + IQR) | ||
Rifabutin (RBT) | |||
Ctrough (ng/mL) | 53 (46–78) | 177 (94–266) | 0.044 |
Cmax (ng/mL) | 296 (205–450) | 600 (403–717) | 0.313 |
Tmax (h) | 3 (2–6) | 4 (2–4) | 0.657 |
AUC0–12 h | 2528 (1684–2735) | 4042.5 (3469–5761) | 0.044 |
Clearance | |||
CL (L/h) | 51.5 (34.1–53.0) | 23.2 (20.1–24.9) | 0.044 |
CL (L/h/kg) | 0.92 (0.63–1.02) | 0.84 (0.78–1.00) | 1.000 |
25-O-desacetyl-rifabutin (d-RBT) | |||
Ctrough (ng/mL) | 61 (39–65) | 103 (79–126) | 0.044 |
Cmax (ng/mL) | 129 (111–157) | 160 (136–345) | 0.313 |
Tmax (h) | 6 (2–8) | 3 (3–4) | 0.242 |
AUC0–12 h (ng.h/mL) | 1200.5 (737.5–1295.5) | 1534 (1059.5–2351) | 1.000 |
Data are presented as medians with the range in parentheses
RBT rifabutin, d-RBT 25-O-desacetyl-rifabutin, EOD every other day (every 48 h), LPV/r lopinavir/ritonavir, CTn plasma drug concentration at a specified time, IQR interquartile range, Cmax maximum (peak) plasma drug concentration, Tmax Time to reach maximum (peak) plasma concentration following drug administration, C0 trough plasma concentration (measured concentration at the end of a dosing interval at steady state (48 h) [taken directly before next administration]), AUCt0–12h area under the plasma concentration-time curve within time span t0 to t2